OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting

Core Insights - OKYO Pharma Limited has announced that an abstract on its lead candidate, urcosimod, has been accepted for presentation at the 2026 ASCRS Annual Meeting, highlighting the company's progress in developing therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases [1][2][3] Company Overview - OKYO Pharma is a clinical-stage biopharmaceutical company focused on developing innovative therapies for NCP and inflammatory eye diseases, with its shares listed on the Nasdaq Capital Market [8] - The company recently completed a successful Phase 2 trial of urcosimod in patients with NCP and plans to initiate a 150-patient Phase 2b/3 multiple-dose study in the first half of 2026 [5][8] Product Details - Urcosimod, formerly known as OK-101, is a lipid conjugated chemerin peptide agonist targeting the ChemR23 G-protein coupled receptor, which is involved in the inflammatory response and pain reduction [7] - The drug has shown positive efficacy signals in reducing pain and improving corneal nerve health in a proof-of-concept Phase 2 study, with statistical significance in multiple endpoints [4][7] Industry Context - Neuropathic corneal pain is a chronic condition with no FDA-approved therapies specifically for its treatment, leading to a significant unmet medical need [6] - The acceptance of the abstract at the ASCRS Annual Meeting underscores the potential of urcosimod as a first-in-class therapeutic option for patients suffering from NCP [3][4]